TheraRadar
← Back
Data updated: Jun 28, 2026

Viatris

Generics
CardiovascularImmunologyNeurology Execution: Fair

Viatris is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology. Key products include SEMGLEE.

1947
Since
368
Drugs
-
Trials
5
New Drugs (2yr)
Modality:
39 Small Molecules 1 Biologics

FDA Novel Drug Designations

(2018-2019)
2 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 2 novel approvals →
2019 PRETOMANID First-in-Class · Orphan · Priority Review · Fast Track
2018 YUPELRI (REVEFENACIN)

Viatris at a Glance

  • Fast trial execution (4 months median completion)

Viatris's Recent FDA Approvals

Viatris secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

APREPITANT NDA
2026-06-16
aprepitant
Nausea
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections

Viatris's Therapeutic Areas

Viatris's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 1 biologic and 39 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
35 drugs Phase 3: 4 Phase 2: 2 Phase 1: 14
Immunology 18%
17 drugs Phase 3: 7 Phase 2: 2 Phase 1: 2
Neurology 18%
14 drugs Phase 3: 12 Phase 1: 1
Respiratory 18%
13 drugs Phase 3: 8 Phase 2: 6 Phase 1: 9
Oncology 13%
15 drugs Phase 3: 2

Viatris Pipeline Snapshot

Viatris has 69 active clinical programs from ClinicalTrials.gov — 33 Phase 3, 10 Phase 2 and 26 Phase 1.

33
Phase 3
10
Phase 2
26
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q1 2027
Transdermal system containing progestin
Female Contraception
Estimated · fresh NCT06672016

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/5 completed
  • • Speed: 4 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges